Skip to main content
SpringerLink
Log in

Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein

  • Short communication
  • Published:
Pharmacological Reports Aims and scope Submit manuscript

Abstract

The reduced bioavailability of nimodipine after oral administration might not only be due to the metabolizing enzyme cytochrome P450 3A4(CYP3A4) but also to the P-glycoprotein efflux transporter in the small intestine. The aim of this study was to investigate the effects of baicalein on the pharmacokinetics of nimodipine in rats. The effect of baicalein on P-glycoprotein and CYP3A4 activity was evaluated. A single dose of nimodipine was administered intravenously (3 mg/kg) and orally (12 mg/kg) to rats in the presence and absence of baicalein (0.4, 2 and 8 mg/kg). Baicalein inhibited CYP3A4 enzyme activity in a concentration-dependent manner, with a 50% inhibition concentration (IC50) of 9.2 μM. In addition, baicalein significantly enhanced the cellular accumulation of rhodamine-123 in MCF-7/ADR cells overexpressing P-glycoprotein. Baicalein significantly altered the pharmacokinetics of orally administered nimodipine. Compared to the oral control group given nimodipine alone, the area under the plasma concentration-time curve (AUC0-∞) and the peak plasma concentration (Cmax) of nimodipine significantly increased (p < 0.05 for 2 mg/kg; p < 0.01 for 8 mg/kg). Consequently, the absolute bioavailability of nimodipine in the presence of baicalein (2 and 8 mg/kg) was 31.0–35.3%, which was significantly enhanced (p <0.05 for 2 mg/kg; p <0.01 for 8 mg/kg) compared to the oral control group (22.3%). Moreover, the relative bioavailability of nimodipine was 1.39- to 1.58-fold greater than that of the control group. The pharmacokinetics of intravenous nimodipine were not affected by baicalein in contrast to those of oral nimodipine. Baicalein significantly enhanced the oral bioavailability of nimodipine, which may be mainly due to inhibition of the CYP3A4-mediated metabolism of nimodipine in the small intestine and/or in the liver and the inhibition of the P-glycoprotein efflux pump in the small intestine by baicalein. The increase in oral bioavailability of nimodipine in the presence of baicalein should be taken into consideration as a potential drug interaction between nimodipine and baicalein.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Chieli E, Romiti N, Cervelli F, Tongiani R: Effects of flavonols on P-glycoprotein activity in cultured rat hepatocytes. Life Sci, 1995, 57, 1741–1751.

    Article  CAS  Google Scholar 

  2. Choi JS, Burm JP: Enhanced nimodipine bioavailability after oral administration of nimodipine with morin, a flavonoid, in rabbits. Arch Pharm Res, 2006, 29, 333–338.

    Article  CAS  Google Scholar 

  3. Crespi CL, Miller VP, Penman BW: Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem, 1997, 248, 188–190.

    Article  CAS  Google Scholar 

  4. Cummins CL, Jacobsen W, Benet LZ: Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther, 2002, 300, 1036–1045.

    Article  CAS  Google Scholar 

  5. Di Pietro A, Conseil G, Pérez-Victoria JM, Dayan G, Baubichon-Cortay H, Trompier D, Steinfels E etal.: Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol Life Sci, 2002, 59, 307–322.

    Article  Google Scholar 

  6. Dixon RA, Steel CL: Flavonoids and isoflavonoids — a gold mine for metabolic engineering. Trend Plant Sci, 1999, 4, 394–400.

    Article  CAS  Google Scholar 

  7. Epstein M, Loutzenhister RD: Effects of calcium antagonists on renal hemodynamics. Am J Kidney Dis, 1990, 16, 10–14.

    CAS  PubMed  Google Scholar 

  8. Gan LL, Moseley MA, Khosla B, Augustijns PF, Bradshaw TP, Hendren RW, Thakker DR: CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab Dispos, 1996, 24, 344–349.

    CAS  PubMed  Google Scholar 

  9. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem, 1993, 62, 385–427.

    Article  CAS  Google Scholar 

  10. Ito K, Kusuhara H, Sugiyama Y: Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm Res, 1999, 16, 225–231.

    Article  CAS  Google Scholar 

  11. Kaminsky LS, Fasco MJ: Small intestinal cytochromes P450. Crit Rev Toxicol, 1991, 21, 407–422.

    Article  CAS  Google Scholar 

  12. Kazda S, Garthoff B, Krause HP, Schlossmann K: Cerebrovascular effects of the calcium antagonistic dihy-dropyridine derivative nimodipine in animal experiments. Arzneimittelforschung, 1982, 32, 331–338.

    CAS  PubMed  Google Scholar 

  13. Kitagawa S, Nabekura T, Takahashi T, Nakamura Y, Sakamoto H, Tano H, Hirai M, Tsukahara G: Structure-activity relationships of the inhibitory effects of fla-vonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol Pharm Bull, 2005, 28, 2274–2278.

    Article  CAS  Google Scholar 

  14. Lee H, Wang HW, Su HY, Hao NJ: The structure-activity relationships of flavonoids as inhibitors of cytochrome P-450 enzymes in rat liver microsomes and the mutagenicity of 2-amino-3-methyl-imidazo[4,5-f]quinoline. Mutagenesis, 1994, 9, 101–106.

    Article  CAS  Google Scholar 

  15. Lee Y, Yeo H, Liu SH, Jiang Z, Savizky RM, Austin DJ, Cheng YC: Increased anti-P-glycoprotein activity of baicalein by alkylation on a ring. J Med Chem, 2004, 47, 5555–5566.

    Article  CAS  Google Scholar 

  16. Lin CC, Shieh DE: The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am J Chinese Med, 1996, 24, 31–36.

    Article  CAS  Google Scholar 

  17. Liu A, Yang J, Zhao X, Jiao X, Zhao W, Ma Q, Tang Z, Dai R: Induction of P450 3A1/2 and 2C6 by gemfibrozil in Sprague-Dawley rats. Pharmacol Rep, 2011, 63, 157–164.

    Article  CAS  Google Scholar 

  18. Manach C, Regerat F, Texier O, Agullo G, Demigne C, Remesy C: Bioavailability, metabolism and physiological impact of 4-oxo-flavonoids. Nutr Res, 1996, 16, 517–544.

    Article  CAS  Google Scholar 

  19. Maruhn D, Siefert HM, Weber H, Ramsch K, Suwelack D: Pharmacokinetics of nimodipine. communication: absorption, concentration in plasma and excretion after single administration of nimodipine in rat, dog and monkey. Arzneimittelforschung, 1985, 5, 1781–1786.

    Google Scholar 

  20. Matsuzaki Y, Kurokawa N, Terai S, Matsumura Y, Kobayashi N, Okita K: Cell death induced by baicalein in human hepatocellular carcinoma cell lines. Jpn J Cancer Res, 1996, 87, 170–177.

    Article  CAS  Google Scholar 

  21. Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA: Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr, 2001, 74, 418–425.

    Article  CAS  Google Scholar 

  22. Qian M, Gallo JM: High-perfomance liquid chromatographic determinination of the calcium channel blocker nimodipine in monkey plasma. J Chromatogr B, 1992, 578, 316–320.

    Article  CAS  Google Scholar 

  23. Ramsch KD, Ahr G, Tettenborn D, Auer LM: Overview on pharmacokinetics of nimodipine in healthy volunteer and in patients with subarachnoid hemorrhage. Neurochirurgia, 1985, 28, 74–78.

    PubMed  Google Scholar 

  24. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS Lett, 1993, 324, 99–102.

    Article  CAS  Google Scholar 

  25. Sagara K, Ito Y, Oshima T, Misaki T, Murayama H, Itokawa H: Simultaneous determination of baicalein, wogonin, oroxylin-A and their glucuronides in Scutellariae radix by ion-pair high-performance liquid chromatography. J Chromatogr A, 1985, 328, 289–297.

    Article  CAS  Google Scholar 

  26. Scherling D, Buhner K, Krause HP, Karl W, Wunsche C: Biotransformation of nimodipine in rat, dog and monkey. Arzneimittelforschung, 1991, 41, 392–398.

    CAS  PubMed  Google Scholar 

  27. Scholz H: Pharmacological aspects of calcium channel blockers. Cardiovasc Drugs Ther. 1997, 10, 869–872.

    Article  Google Scholar 

  28. Shin SC, Li C, Choi JS: Effects of baicalein, an antioxidant, on the bioavailability of doxorubin in rats. Phar-mazie, 2009, 64, 579–583.

    CAS  Google Scholar 

  29. Sutherland L, Ebner T, Burchell B: The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem Pharmacol, 1993, 45, 295–301.

    Article  CAS  Google Scholar 

  30. Suwelack D, Weber H, Maruhn D: Pharmacokinetics of nimodipine, communication: absorption, concentration in plasma and excretion after single administration of nimodipine in rat, dog and monkey. Arzneimittelforschung, 1985, 35, 1787–1794.

    CAS  PubMed  Google Scholar 

  31. Turgeon D, Carrier JS, Lévesque E, Hum DW, Bélanger A: Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology, 2001, 142, 778–787.

    Article  CAS  Google Scholar 

  32. Takino Y, Miyahara T, Arichi E, Arichi S, Hayashi T, Karikura M: Determination of some flavonoids in Scutellariae radix by high-performance liquid chromatography. Chem Pharm Bull, 1987, 35, 3494–3497.

    Article  CAS  Google Scholar 

  33. Wacher VH, Silverman JA, Zhang Y, Benet LZ: Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci, 1998, 87, 1322–1330.

    Article  CAS  Google Scholar 

  34. Watkins PB: The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Pharm Drug Deliv Rev, 1996, 27, 161–170.

    Article  Google Scholar 

  35. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol, 2000, 10, 1439–1443.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, Research Institute of Life Science, Gyeongsang National University, Jinju, 660-701, Republic of Korea

    Young-Ah Cho

  2. College of Pharmacy, Chosun University, Gwangju, 501-759, Republic of Korea

    Jun-Shik Choi

  3. College of Nursing, Chosun Nursing College, Gwangju, 501-825, Republic of Korea

    Jin-Pil Burm

Authors
  1. Young-Ah Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun-Shik Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jin-Pil Burm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jin-Pil Burm.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cho, YA., Choi, JS. & Burm, JP. Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein. Pharmacol. Rep 63, 1066–1073 (2011). https://doi.org/10.1016/S1734-1140(11)70624-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/S1734-1140(11)70624-7

Key words

Search

Navigation